Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REPORTS SECOND-QUARTER DILUTED EPS OF $2.03 ON A GAAP BASIS, AN INCREASE OF 290.4 PERCENT; ADJUSTED DILUTED EPS OF $3.65, AN INCREASE OF 22.9 PERCENT; THESE RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.17 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE DELIVERS SECOND-QUARTER NET REVENUES OF $16.990 BILLION, AN INCREASE OF 10.2 PERCENT ON A REPORTED BASIS OR 9.5 PERCENT ON AN OPERATIONAL BASIS SECOND-QUARTER GLOBAL NET REVENUES FROM THE IMMUNOLOGY PORTFOLIO WERE $8.786 BILLION, AN INCREASE OF 15.1 PERCENT ON A REPORTED BASIS, OR 14.6 PERCENT ON AN OPERATIONAL BASIS; GLOBAL SKYRIZI NET REVENUES WERE $5.505 BILLION; GLOBAL RINVOQ NET REVENUES WERE $2.525 BILLION; GLOBAL HUMIRA NET REVENUES WERE $756 MILLION SECOND-QUARTER GLOBAL NET REVENUES FROM THE NEUROSCIENCE PORTFOLIO WERE $3.228 BILLION, AN INCREASE OF 20.3 PERCENT ON A REPORTED BASIS, OR 19.8 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VRAYLAR NET REVENUES WERE $1.071 BILLION; GLOBAL BOTOX THERAPEUTIC NET REVENUES WERE $1.042 BILLION; COMBINED GLOBAL UBRELVY AND QULIPTA NET REVENUES WERE $742 MILLION; GLOBAL VYALEV NET REVENUES WERE $256 MILLION SECOND-QUARTER GLOBAL NET REVENUES FROM THE ONCOLOGY PORTFOLIO WERE $1.650 BILLION, A DECREASE OF 1.5 PERCENT ON A REPORTED BASIS, OR 2.4 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VENCLEXTA NET REVENUES WERE $771 MILLION; GLOBAL IMBRUVICA NET REVENUES WERE $532 MILLION; GLOBAL ELAHERE NET REVENUES WERE $211 MILLION SECOND-QUARTER GLOBAL NET REVENUES FROM THE AESTHETICS PORTFOLIO WERE $1.282 BILLION, AN INCREASE OF 0.3 PERCENT ON A REPORTED BASIS, OR A DECREASE OF 0.9 PERCENT ON AN OPERATIONAL BASIS; GLOBAL BOTOX COSMETIC NET REVENUES WERE $728 MILLION; GLOBAL JUVEDERM NET REVENUES WERE $245 MILLION ANNOUNCED DEFINITIVE AGREEMENT TO ACQUIRE APOGEE THERAPEUTICS, DEEPENING ABBVIE'S IMMUNOLOGY PORTFOLIO UPDATES 2026 ADJUSTED DILUTED EPS GUIDANCE RANGE FROM $13.91 - $14.11 TO $13.87 - $14.07; NOW INCLUDES A $0.14 PER SHARE DILUTIVE IMPACT RELATED TO THE PROPOSED ACQUISIT

ABBVIE REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF APOGEE THERAPEUTICS, INC. (NASDAQGM: APGE) TO ABBVIE (NYSE: ABBV). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF APOGEE WILL RECEIVE $135.11 IN CASH FOR EACH SHARE OF APOGEE THAT THEY OWN. KSF IS SEEKING TO DETERMINE WHETHER THIS CONSIDERATION AND THE PROCESS THAT LED TO IT ARE A.

APOGEE THERAPEUTICS INVESTOR ALERT: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF APOGEE THERAPEUTICS, INC. - APGE

ALLERGAN AESTHETICS CELEBRATES FOURTH ANNUAL JUVDERM  DAY WITH BUY-ONE-GET-ONE (BOGO) GIFT CARDS AND DOUBLE POINTS FOR ALL MEMBERS THIS SUMMER MARKS THE 20TH ANNIVERSARY OF THE BRAND'S FIRST U.S. FOOD AND DRUG ADMINISTRATION (FDA) DERMAL FILLER APPROVAL JOIN ALL TODAY TO TAKE ADVANTAGE OF LIMITED TIME OFFERS, WHILE SUPPLIES LAST NORTH CHICAGO, ILL., JULY 30, 2026 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), TODAY ANNOUNCED THE RETURN OF JUVDERMDAYON WEDNESDAY, AUGUST 19, 2026, WITH EXCLUSIVE JUVDERMOFFERS FOR ALLMEMBERS.

JUVDERM DAY RETURNS TO U.S. ON AUGUST 19

RINVOQ IS THE FIRST AND ONLY SYSTEMIC MEDICATION APPROVED IN THE EUROPEAN UNION TO TREAT ADULT AND ADOLESCENT PATIENTS WITH NON-SEGMENTAL VITILIGO (NSV) THE APPROVAL IS SUPPORTED BY DATA FROM THE PHASE 3 VITI-UP CLINICAL PROGRAM, WHICH SHOWED THAT RINVOQ ACHIEVED STATISTICALLY SIGNIFICANT TOTAL BODY (T-VASI 50) AND FACIAL REPIGMENTATION (F-VASI 75) FROM BASELINE AT WEEK 48, VERSUS PLACEBO 1 NORTH CHICAGO, ILL., JULY 29, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS APPROVED RINVOQ(UPADACITINIB; 15 MG, ONCE DAILY) FOR THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH NON-SEGMENTAL VITILIGO (NSV) WHO ARE CANDIDATES FOR SYSTEMIC THERAPY.1WITH THIS APPROVAL, RINVOQ IS NOW THE FIRST AND ONLY SYSTEMIC MEDICATION APPROVED IN THE EUROPEAN UNION FOR NSV, THE MOST COMMON FORM OF VITILIGO.2 "THE EUROPEAN COMMISSION'S APPROVAL OF RINVOQ AS THE FIRST AND ONLY SYSTEMIC TREATMENT FOR NON-SEGMENTAL VITILIGO IS AN ADVANCEMENT FOR PATIENTS LIVING WITH THIS CHRONIC AUTOIMMUNE DISEASE," SAID ROOPAL THAKKAR, M.D.

ABBVIE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF RINVOQ (UPADACITINIB) FOR THE TREATMENT OF ADULTS AND ADOLESCENTS WITH NON-SEGMENTAL VITILIGO

RINVOQ  IS NOW APPROVED IN THE EUROPEAN UNION FOR THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS WITH SEVERE ALOPECIA AREATA (AA) APPROVAL WAS BASED ON THE PIVOTAL PHASE 3 UP-AA CLINICAL PROGRAM, WHICH SHOWED THAT RINVOQ ACHIEVED STATISTICALLY SIGNIFICANT SCALP HAIR REGROWTH (SEVERITY OF ALOPECIA TOOL (SALT) SCORE  20) AND IMPROVEMENTS IN EYEBROWS AND EYELASHES AT WEEK 24 1 RINVOQ IS THE FIRST JAK INHIBITOR TO ACHIEVE COMPLETE SCALP HAIR REGROWTH (SALT = 0) VERSUS PLACEBO AT WEEK 24 NORTH CHICAGO, ILL., JULY 29, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS APPROVED RINVOQ(UPADACITINIB; 15 MG AND 30 MG, ONCE DAILY) FOR THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH SEVERE ALOPECIA AREATA (AA).1 "THE EUROPEAN COMMISSION'S APPROVAL OF RINVOQ PROVIDES A NEW TREATMENT OPTION FOR THE SEVERE ALOPECIA AREATA COMMUNITY IN THE EU WITH DEMONSTRATED SCALP REGROWTH, INCLUDING COMPLETE SCALP HAIR REGROWTH FOR SOME, THAT CAN SUPPORT MANAGEMENT OF THE DISEASE," SAID ROOPAL THAKKAR, M.D.

ABBVIE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF RINVOQ (UPADACITINIB) FOR THE TREATMENT OF ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA

COPENHAGEN, DENMARK & NORTH CHICAGO, ILL.--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) AND ABBVIE (NYSE: ABBV) TODAY PROVIDED CLARIFICATION ON THE PRIMARY ENDPOINTS FROM THE PHASE 3 EPCORE DLBCL-1 STUDY EVALUATING MONOTHERAPY EPCORITAMAB (DUOBODY-CD3XCD20), A T-CELL ENGAGING BISPECIFIC ANTIBODY ADMINISTERED SUBCUTANEOUSLY, COMPARED WITH INVESTIGATOR'S CHOICE OF CHEMOIMMUNOTHERAPY (CIT) OF EITHER RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN ADULTS.

GENMAB AND ABBVIE PROVIDE CLARIFICATION ON PHASE 3 EPCORE DLBCL-1 TRIAL EVALUATING EPCORITAMAB (DUOBODY-CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

BOEY IS THE FIRST AND ONLY RAPID-ONSET AND SHORT-DURATION BOTULINUM NEUROTOXIN SEROTYPE E APPROVED IN EUROPE THAT ADULT PATIENTS CAN TRY FOR THE TEMPORARY IMPROVEMENT OF GLABELLAR LINES RESULTS MAY BE SEEN AS EARLY AS EIGHT HOURS AFTER TREATMENT AND TYPICALLY WEAR OFF WITHIN APPROXIMATELY TWO TO THREE WEEKS BOEY OFFERS A DIFFERENTIATED TREATMENT OPTION FOR MANY PEOPLE WHO ARE CURIOUS ABOUT FACIAL INJECTABLES NORTH CHICAGO, ILL., JULY 17, 2026 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), ANNOUNCED THE EUROPEAN COMMISSION HAS APPROVED BOEY(TRENIBOTULINUMTOXINE) IN EUROPE, FOR THE TEMPORARY IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE LINES BETWEEN THE EYEBROWS SEEN AT MAXIMUM FROWN (GLABELLAR LINES) IN ADULT PATIENTS, WHEN THESE HAVE AN IMPORTANT PSYCHOLOGICAL IMPACT.1 FOLLOWING COMPLETION OF THE CENTRALIZED PROCEDURE, THE EUROPEAN COMMISSION DECISION APPLIES ACROSS ALL 30 EUROPEAN ECONOMIC AREA (EEA) COUNTRIES.

ALLERGAN AESTHETICS RECEIVES APPROVAL FOR BOEY (TRENIBOTULINUMTOXINE), FOR USE IN EUROPE: THE FIRST AND ONLY RAPID-ONSET, SHORT-DURATION NEUROTOXIN FOR THE TEMPORARY IMPROVEMENT OF FROWN LINES IN ADULT PATIENTS

SKINMEDICA  LAUNCHES REGENERATIVE SCIENCE ADVISORY BOARD TO SHAPE FUTURE INNOVATION EXPANDS ITS STATE-OF-THE-ART RESEARCH AND DEVELOPMENT (R&D) FACILITY TO SUPPORT THE NEXT GENERATION OF SCIENCE-LED INNOVATION DEBUTS FLAGSHIP RETAIL EXPERIENCES DESIGNED TO SUPPORT PRACTICE AND PATIENTS' NEEDS IRVINE, CALIF., JULY 14, 2026 /PRNEWSWIRE/ --ALLERGAN AESTHETICS, AN ABBVIE (NYSE: ABBV) COMPANY, IS PROUD TO ANNOUNCE SKINMEDICA'S EXPANDED COMMITMENT TO REGENERATIVE SCIENCE, ADVANCING INVESTMENTS THAT WILL SUPPORT INNOVATION, RESEARCH, CLINICAL INSIGHT, AND PATIENT EXPERIENCE.

SKINMEDICA DEEPENS COMMITMENT TO REGENERATIVE SCIENCE WITH CONTINUED INVESTMENT IN RESEARCH AND DEVELOPMENT

TEPKINLY  (EPCORITAMAB) PLUS LENALIDOMIDE AND RITUXIMAB (R 2 ) IS THE FIRST AND ONLY BISPECIFIC-BASED THERAPY APPROVED IN EUROPE FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN THE SECOND-LINE SETTING, OFFERING A CHEMOTHERAPY-FREE OPTION IN THE PHASE 3 EPCORE  FL-1 TRIAL, FIXED-DURATION TEPKINLY + R 2 ACHIEVED STATISTICALLY SIGNIFICANT IMPROVEMENT OF PROGRESSION-FREE SURVIVAL AND OVERALL RESPONSE RATES COMPARED TO R 2 , WITH APPROXIMATELY THREE OUT OF FOUR PATIENTS ACHIEVING A COMPLETE RESPONSE NORTH CHICAGO, ILL., JULY 6, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) GRANTED MARKETING AUTHORIZATION FOR TEPKINLY (EPCORITAMAB) IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB (TEPKINLY + R2) FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL).

ABBVIE ANNOUNCES TEPKINLY (EPCORITAMAB) IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IS APPROVED BY THE EUROPEAN COMMISSION FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

TOPLINE RESULTS FROM PHASE 3 EPCORE  DLBCL-4 TRIAL EVALUATING EPCORITAMAB IN COMBINATION WITH LENALIDOMIDE DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PROGRESSION-FREE SURVIVAL (PFS) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) EPCORE DLBCL-4 DEMONSTRATED IMPROVED PFS WITH A CHEMOTHERAPY-FREE COMBINATION TREATMENT REGIMEN IN PATIENTS WITH R/R DLBCL NORTH CHICAGO, ILL., JUNE 29, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED TOPLINE RESULTS FROM THE PHASE 3 EPCORE DLBCL-4 TRIAL EVALUATING THE COMBINATION OF EPCORITAMAB, A T-CELL ENGAGING BISPECIFIC ANTIBODY, AND LENALIDOMIDE, COMPARED TO RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WHO RECEIVED AT LEAST ONE PRIOR LINE OF THERAPY.

ABBVIE ANNOUNCES POSITIVE PHASE 3 RESULTS FOR EPCORITAMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

POSITIVE CHMP OPINION IS SUPPORTED BY DATA FROM THE PHASE 3 UP-AA CLINICAL PROGRAM IN WHICH UPADACITINIB ACHIEVED THE PRIMARY ENDPOINT OF SEVERITY OF ALOPECIA TOOL (SALT) SCORE  20 AND KEY SECONDARY ENDPOINTS, INCLUDING IMPROVEMENTS IN EYEBROWS AND EYELASHES, AT WEEK 24 1,2 UPADACITINIB IS THE FIRST JAK INHIBITOR TO MEET THE STRINGENT RANKED SECONDARY ENDPOINT OF COMPLETE SCALP HAIR REGROWTH (SALT = 0) AT WEEK 24 1,2 NORTH CHICAGO, ILL., JUNE 29, 2026 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION RECOMMENDING THE APPROVAL OF UPADACITINIB (RINVOQ; 15 MG AND 30 MG, ONCE DAILY) FOR THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS WITH SEVERE ALOPECIA AREATA (AA).

ABBVIE RECEIVES POSITIVE CHMP OPINION FOR UPADACITINIB (RINVOQ) FOR THE TREATMENT OF ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA

IF APPROVED, UPADACITINIB IS EXPECTED TO BE THE FIRST SYSTEMIC MEDICATION FOR PATIENTS WITH NON-SEGMENTAL VITILIGO, ADDRESSING IMPORTANT TREATMENT NEEDS FOR THOSE LIVING WITH THE CHRONIC, UNPREDICTABLE AUTOIMMUNE DISEASE POSITIVE CHMP OPINION IS SUPPORTED BY DATA FROM THE PHASE 3 VITI-UP CLINICAL STUDIES, IN WHICH UPADACITINIB ACHIEVED BOTH CO-PRIMARY ENDPOINTS DEMONSTRATING AT LEAST A 50% IMPROVEMENT IN TOTAL BODY REPIGMENTATION (T-VASI 50) AND AT LEAST A 75% IMPROVEMENT IN FACIAL REPIGMENTATION (F-VASI 75) FROM BASELINE AT WEEK 48 1 NORTH CHICAGO, ILL., JUNE 29, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HASADOPTED A POSITIVE OPINION RECOMMENDING THE APPROVAL OF UPADACITINIB (RINVOQ; 15 MG, ONCE DAILY) FOR THE TREATMENT OF ADULT AND ADOLESCENT PATIENTS WITH NON-SEGMENTAL VITILIGO (NSV).

ABBVIE RECEIVES POSITIVE CHMP OPINION FOR UPADACITINIB (RINVOQ) FOR THE TREATMENT OF ADULTS AND ADOLESCENTS WITH NON-SEGMENTAL VITILIGO

SKYRIZI (RISANKIZUMAB-RZAA) IS NOW APPROVED FOR PATIENTS SIX YEARS OF AGE AND OLDER WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OR ACTIVE PSORIATIC ARTHRITIS APPROVAL INCLUDES A NEW 55 MG PRE-FILLED SYRINGE TO SUPPORT WEIGHT-BASED DOSING FOR THOSE PATIENTS WEIGHING LESS THAN 40 KG SKYRIZI BECOMES THE FIRST AND ONLY IL-23 INHIBITOR APPROVED IN THE U.S. FOR PEDIATRIC PATIENTS SIX YEARS OF AGE AND OLDER WEIGHING LESS THAN 40 KG WITH PLAQUE PSORIASIS OR PSORIATIC ARTHRITIS NORTH CHICAGO, ILL., JUNE 26, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED SKYRIZI (RISANKIZUMAB-RZAA) FOR THE TREATMENT OF CHILDREN SIX YEARS OF AGE AND OLDER WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY, OR ACTIVE PSORIATIC ARTHRITIS.

SKYRIZI (RISANKIZUMAB-RZAA) NOW FDA APPROVED FOR PEDIATRIC USE IN PSORIATIC DISEASE

NORTH CHICAGO, ILL., JUNE 26, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) WILL ANNOUNCE ITS SECOND-QUARTER 2026 FINANCIAL RESULTS ON FRIDAY, JULY 31, 2026, BEFORE THE MARKET OPENS.

ABBVIE TO HOST SECOND-QUARTER 2026 EARNINGS CONFERENCE CALL

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF APOGEE THERAPEUTICS, INC. (NASDAQGM: APGE) TO ABBVIE (NYSE: ABBV). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF APOGEE WILL RECEIVE $135.11 IN CASH FOR EACH SHARE OF APOGEE THAT THEY OWN. KSF IS SEEKING TO DETERMINE WHETHER THIS CONSIDERATION AND THE PROCESS THAT LED TO IT ARE ADEQUA.

250 WOMEN ENTREPRENEURS HAVE BEEN SELECTED TO JOIN A MULTI-WEEK SKILL-BUILDING, MENTORSHIP, AND NETWORKING PROGRAM BOTOX COSMETIC WILL AWARD 20 PARTICIPANTS WITH $20,000 GRANTS EACH TO HELP TAKE THEIR BUSINESS DREAMS TO THE NEXT LEVEL IRVINE, CALIF., JUNE 24, 2026 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), TODAY ANNOUNCED THE 2026 COHORT OF ENTREPRENEURS SELECTED TO PARTICIPATE IN THE CONFIDENCE COLLECTIVE: EMPOWERING WOMEN ENTREPRENEURS, AN ONGOING INITIATIVE FROM BOTOX COSMETIC DEDICATED TO UPLIFTING AND INVESTING IN WOMEN BUSINESSOWNERS.

BOTOX COSMETIC (ONABOTULINUMTOXINA) INTRODUCES THE CONFIDENCE COLLECTIVE'S ENTREPRENEUR CLASS OF 2026

CANADA IS THE FIRST COUNTRY TO APPROVE A NEW BOTULINUM NEUROTOXIN SEROTYPE FOR AESTHETIC USE BOEY  IS THE FIRST AND ONLY RAPID-ONSET AND SHORT-DURATION BOTULINUM NEUROTOXIN SEROTYPE E APPROVED FOR THE TEMPORARY IMPROVEMENT IN THE APPEARANCE OF GLABELLAR LINES BOEY OFFERS A DIFFERENTIATED TREATMENT OPTION FOR MANY PEOPLE WHO ARE CURIOUS ABOUT FACIAL INJECTABLES RESULTS MAY BE SEEN AS EARLY AS EIGHT HOURS AFTER TREATMENT AND TYPICALLY WEAR OFF WITHIN APPROXIMATELY TWO TO THREE WEEKS BOTOX COSMETIC  (ONABOTULINUMTOXINA) IS THE ONLY NEUROTOXIN CLINICALLY TESTED FOR USE FOLLOWING TREATMENT WITH BOEY  IRVINE, CALIF., JUNE 23, 2026 /PRNEWSWIRE/ -- TODAY, ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), ANNOUNCED HEALTH CANADA HAS APPROVED BOEY (TRENIBOTULINUMTOXINE) FOR THE TEMPORARY IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE LINES BETWEEN THE EYEBROWS (GLABELLAR LINES) IN ADULT PATIENTS.

ALLERGAN AESTHETICS RECEIVES APPROVAL FOR BOEY (TRENIBOTULINUMTOXINE) IN CANADA, THE FIRST AND ONLY RAPID-ONSET, SHORT-DURATION NEUROTOXIN FOR THE TEMPORARY IMPROVEMENT OF FROWN LINES IN ADULT PATIENTS

MAVIRET  (GLECAPREVIR/PIBRENTASVIR) IS NOW APPROVED IN THE EUROPEAN UNION FOR THE TREATMENT OF ACUTE HEPATITIS C VIRUS (HCV) INFECTION WITH COMPENSATED LIVER DISEASE (WITH OR WITHOUT CIRRHOSIS) IN ADULTS AND CHILDREN AGED 3 YEARS AND OLDER. THE APPROVAL GIVES CLINICIANS AN OPTION TO INITIATE TREATMENT AS SOON AS ACUTE INFECTION IS CONFIRMED, AIMING TO REDUCE DELAYS IN CARE AND LOWER THE RISK OF LIVER DISEASE PROGRESSION, CIRRHOSIS AND LIVER CANCER.

ABBVIE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF MAVIRET (GLECAPREVIR/PIBRENTASVIR) FOR PEOPLE WITH ACUTE HEPATITIS C VIRUS INFECTION

SKYRIZI  (RISANKIZUMAB) EXPANDS ITS INDICATION FOR CHILDREN AND ADOLESCENTS SIX YEARS OF AGE AND OLDER WITH MODERATE TO SEVERE PLAQUE PSORIASIS 1 APPROVAL WAS BASED ON THE PIVOTAL PHASE 3 OPTIMMIZE-1 AND OPTIMMIZE-2 TRIALS WHICH INCLUDE A NEW 55 MG PRE-FILLED SYRINGE TO SUPPORT WEIGHT-BASED DOSING FOR PATIENTS WEIGHING LESS THAN 40 KG 1 NEARLY A THIRD OF PEOPLE LIVING WITH PSORIASIS DEVELOP SYMPTOMS BEFORE THE AGE OF 18, OFTEN GETTING LESIONS ON HIGHLY VISIBLE AREAS 2,3 NORTH CHICAGO, ILL., JUNE 23, 2026 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS APPROVED SKYRIZI (RISANKIZUMAB) FOR THE TREATMENT OF CHILDREN AND ADOLESCENTS SIX YEARS OF AGE AND OLDER WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY.

ABBVIE ANNOUNCES EUROPEAN COMMISSION APPROVAL OF SKYRIZI (RISANKIZUMAB) FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

PROPOSED ACQUISITION ADDS A DIVERSE PIPELINE OF ASSETS FOCUSED ON ELEVATING THE STANDARD OF CARE FOR PATIENTS WITH DERMATOLOGIC, RESPIRATORY AND OTHER RELATED INFLAMMATORY AND IMMUNOLOGICAL DISEASES APOGEE'S LEAD ASSET, ZUMILOKIBART (APG777), IS A LATE-STAGE, HALF-LIFE EXTENDED MONOCLONAL ANTIBODY TARGETING IL-13, IN DEVELOPMENT FOR PATIENTS WITH ATOPIC DERMATITIS APOGEE'S PIPELINE ALSO INCLUDES COMBINATIONS OF ITS NOVEL ANTIBODIES; APG273, A POTENTIAL BEST-IN-CATEGORY LONG-ACTING COMBINATION TARGETING IL-13 AND THYMIC STROMAL LYMPHOPOIETIN (TSLP), IS BEING DEVELOPED IN ASTHMA APOGEE SHAREHOLDERS TO RECEIVE $135.11 PER SHARE IN CASH, FOR A TOTAL EQUITY VALUE OF APPROXIMATELY $10.9 BILLION ABBVIE TO HOLD INVESTOR CONFERENCE CALL TODAY, JUNE 22, AT 8:00 A.M. CT NORTH CHICAGO, ILL.

ABBVIE TO ACQUIRE APOGEE THERAPEUTICS, DEEPENING IMMUNOLOGY PORTFOLIO

NORTH CHICAGO, ILL., JUNE 18, 2026 /PRNEWSWIRE/ -- THE BOARD OF DIRECTORS OF ABBVIE INC. (NYSE: ABBV) TODAY DECLARED A QUARTERLY CASH DIVIDEND OF $1.73 PER SHARE.

ABBVIE DECLARES QUARTERLY DIVIDEND

SKINVIVE BY JUVDERM IS NOW THE FIRST AND ONLY HYALURONIC ACID INJECTABLE APPROVED TO REDUCE HORIZONTAL NECK LINES CAUSED BY "TECH-NECK.1" THIS IS THE SECOND FDA-APPROVED INDICATION FOR SKINVIVE BY JUVDERM, WHICH HAS BEEN APPROVED SINCE 2023 TO IMPROVE SKIN SMOOTHNESS OF THE CHEEKS IN ADULTS.1 IRVINE, CALIF., JUNE 16, 2026 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF SKINVIVE BY JUVDERM TO REDUCE NECK LINES FOR THE IMPROVEMENT OF NECK APPEARANCE IN ADULTS OVER THE AGE OF 21.1 WITH THIS APPROVAL, SKINVIVE BY JUVDERM IS THE FIRST AND ONLY HYALURONIC ACID (HA) INJECTABLE INDICATED TO REDUCE THE APPEARANCE OF NECK WRINKLES AND HELP SKIN RETAIN ITS NATURAL MOISTURE, LEADING TO AN IMPROVED NECK APPEARANCE.1 NECK WRINKLES MAY DEVELOP DUE TO NATURAL AGING, SUN DAMAGE, WEIGHT LOSS, OR "TECH-NECK" CAUSED BY THE HEAD-DOWN POSITION USED FOR PHONES, TABLETS, AND BOOKS.1SKINVIVE BY JUVDERM REDUCES NECK LINES FORMED BY TECH-NECK BY HELPING THE SKIN RETAIN ITS NATURAL MOISTURE, SOFTNESS, AND SMOOTHNESS.1 TREATMENT WITH SKINVIVE BY JUVDERM IS MINIMALLY INVASIVE WITH LITTLE TO NO DOWNTIME AND IS ADMINISTERED USING AN ULTRAFINE NEEDLE OR CANNULA.

ALLERGAN AESTHETICS RECEIVES U.S. FDA APPROVAL FOR SKINVIVE BY JUVDERM FOR THE IMPROVEMENT OF NECK APPEARANCE

NORTH CHICAGO, ILL., JUNE 12, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED NEW PHASE 3 DATA ON A FIXED-DURATION VENETOCLAX-BASED COMBINATION AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2026 CONGRESS TAKING PLACE JUNE 11-14 IN STOCKHOLM, SWEDEN.

ABBVIE PRESENTS NEW DATA AT EHA 2026 CONGRESS FOR VENCLEXTA/VENCLYXTO (VENETOCLAX) IN FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA HIGHLIGHTING LONG-TERM TREATMENT OUTCOMES FOR PATIENTS: NINE-YEAR RESULTS

THE AGENCY'S LETTER CITED MANUFACTURING-RELATED ITEMS AND RAISED NO SAFETY OR EFFICACY CONCERNS. WERSCHLER, A SPOKANE DERMATOLOGIST WHO HAS SERVED AS A CLINICAL TRIAL INVESTIGATOR IN DERMATOLOGY AND AESTHETIC MEDICINE, EXPLAINS HOW A COMPLETE RESPONSE LETTER FUNCTIONS AND WHAT A SEROTYPE E TOXIN COULD ADD TO THE CATEGORY.

FDA ISSUES COMPLETE RESPONSE LETTER FOR ABBVIE'S FAST-ACTING NEUROTOXIN TRENIBOTE; SPOKANE DERMATOLOGIST DR. PHILIP WERSCHLER ON WHAT THE LETTER MEANS

DATA BEING PRESENTED, INCLUDING SIX ORAL PRESENTATIONS, REINFORCE ABBVIE'S LEADERSHIP AND COMMITMENT TO ONGOING RESEARCH TO IMPROVE OUTCOMES FOR PEOPLE LIVING WITH BLOOD CANCERS NORTH CHICAGO, ILL., JUNE 8, 2026 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED IT WILL SHARE NEW DATA AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2026 CONGRESS AND WILL SHOWCASE CLINICAL ADVANCEMENTS FROM RESEARCH PROGRAMS ACROSS MULTIPLE BLOOD CANCERS, INCLUDING MULTIPLE MYELOMA (MM), FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), ACUTE MYELOID LEUKEMIA (AML) AND AMYLOIDOSIS (AL).

AbbVie Inc.

ABBV

Price

Financial Reports

No items found.

Press Releases

AbbVie Inc.

ABBV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ABBV